Abstract
No-reflow phenomenon is a consequence of percutaneous coronary intervention (PCI) which arises most of the time in the setting of myocardial infarction, but can be also the consequence of PCI in stable angina patients (rotatablator ablation technique or angioplasty in saphenous vein grafts). In this review, we summarize two ways of treating the noreflow according to the current literature. First through the pharmacological approach where several compounds have been assessed like adenosine, nitruprusside, verapamil, nicorandil, dipyridamole, epinephrine or cyclosporine. Second through the mechanical approach where few strategies have been examined like intra-aortic ballon pumping or postconditioning. Finally, we provide an algorithm for treating a no-reflow even though no studies showed a beneficial effect in terms of clinical endpoints.
Keywords: No-reflow, slow-flow, myocardial infarction, reperfusion
Current Vascular Pharmacology
Title:Myocardial No-Reflow Treatment
Volume: 11 Issue: 2
Author(s): Olivier Muller, Catalina Trana and Eric Eeckhout
Affiliation:
Keywords: No-reflow, slow-flow, myocardial infarction, reperfusion
Abstract: No-reflow phenomenon is a consequence of percutaneous coronary intervention (PCI) which arises most of the time in the setting of myocardial infarction, but can be also the consequence of PCI in stable angina patients (rotatablator ablation technique or angioplasty in saphenous vein grafts). In this review, we summarize two ways of treating the noreflow according to the current literature. First through the pharmacological approach where several compounds have been assessed like adenosine, nitruprusside, verapamil, nicorandil, dipyridamole, epinephrine or cyclosporine. Second through the mechanical approach where few strategies have been examined like intra-aortic ballon pumping or postconditioning. Finally, we provide an algorithm for treating a no-reflow even though no studies showed a beneficial effect in terms of clinical endpoints.
Export Options
About this article
Cite this article as:
Muller Olivier, Trana Catalina and Eeckhout Eric, Myocardial No-Reflow Treatment, Current Vascular Pharmacology 2013; 11 (2) . https://dx.doi.org/10.2174/1570161111311020015
DOI https://dx.doi.org/10.2174/1570161111311020015 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms of Dexamethasone-Induced Hypertension
Current Hypertension Reviews Male Contraception: An Overview of the Potential Target Events
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting TRPs in Neurodegenerative Disorders
Current Topics in Medicinal Chemistry Effect of Heart Rate on Arterial Stiffness as Assessed by Pulse Wave Velocity
Current Hypertension Reviews Faujasiopsis flexuosa (Lam.) C. Jeffrey (Asteraceae) – A Promising Traditionally used Endemic Medicinal Plant from Mauritius
Current Traditional Medicine The Impact of Comorbid Diabetes Type 2 on Quality of Life in Cancer Patients Undergoing Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Cholesterol: A Prelate in Cell Nucleus and its Serendipity
Current Molecular Medicine The Therapeutic Potential of Angiotensin-(1-7) as a Novel Renin- Angiotensin System Mediator
Mini-Reviews in Medicinal Chemistry Inhibitory Effect of Ebselen on Cerebral Acetylcholinesterase Activity In Vitro: Kinetics and Reversibility of Inhibition
Current Pharmaceutical Design Seeds of Mung Bean (<i>Vigna radiata</i> (L.) R.Wilczek): Taxonomy, Phytochemistry, Medicinal Uses and Pharmacology
Current Bioactive Compounds The Impact of Dementia Development Concurrent with Parkinson's Disease: A New Perspective
CNS & Neurological Disorders - Drug Targets Argemone mexicana: A Boon to Medicinal and Pharmacological Approaches in Current Scenario
Cardiovascular & Hematological Agents in Medicinal Chemistry Cholesterol Homeostasis and Liver X Receptor (LXR) in Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Oral Supplements of <i>Ginkgo biloba</i> Extract Alleviate Neuroinflammation, Oxidative Impairments and Neurotoxicity in Rotenone-Induced Parkinsonian Rats
Current Pharmaceutical Biotechnology Sympathetic Activation in Congestive Heart Failure: Evidence, Consequences and Therapeutic Implications
Current Vascular Pharmacology Mechanisms of the Penetration of Blood-Borne Substances into the Brain
Current Neuropharmacology Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
Current Pharmaceutical Design Inhibition of Tumor Cells Proliferation and Migration by the Flavonoid Furin Inhibitor Isolated From Oroxylum indicum
Current Medicinal Chemistry Modulation of Vascular Function by Perivascular Adipose Tissue: Sex Differences
Current Pharmaceutical Design Targeting the Sarcolemmal Calcium Pump: A Potential Novel Strategy for the Treatment of Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry